Caption Management’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-2,500
Closed -$152K 1349
2023
Q3
$152K Hold
2,500
﹤0.01% 1116
2023
Q2
$165K Buy
+2,500
New +$183K ﹤0.01% 951
2021
Q3
Sell
-2,316
Closed -$960K 1515
2021
Q2
$960K Buy
2,316
+1,058
+84% +$419K 0.01% 909
2021
Q1
$490K Buy
+1,258
New +$619K 0.01% 811
2020
Q4
Sell
-2,316
Closed -$1.62M 979
2020
Q3
$1.62M Buy
2,316
+232
+11% +$181K 0.04% 502
2020
Q2
$1.65M Hold
2,084
0.05% 420
2020
Q1
$1.24M Sell
2,084
-1,853
-47% -$1.81M 0.07% 347
2019
Q4
$4.47M Buy
+3,937
New +$4.28M 0.15% 188
2019
Q2
Sell
-1,930
Closed -$3.93M 660
2019
Q1
$3.93M Buy
+1,930
New +$3.4M 0.22% 135

Other funds holding BLUE

Caption Management's BLUE Position: Q4 2023 in Review

Caption Management sold out of bluebird bio (BLUE) in Q4 2023, closing a stake of 500 shares — an estimated $30.4K sold.

Caption Management first reported a position in BLUE in Q2 2018 and held it in 13 quarters. The position peaked at $2.28M in Q4 2019. 187 funds tracked by Wall St. Rank hold BLUE as of Q4 2023.

  • Caption Management reported no remaining bluebird bio position as of Q4 2023 after selling out during the quarter.
  • Caption Management sold 500 bluebird bio shares in Q4 2023, an estimated $30.4K.
  • Caption Management first reported a position in bluebird bio in Q2 2018 and held it in 13 quarters.
  • Caption Management's bluebird bio position peaked at $2.28M in Q4 2019.
  • 187 funds tracked by Wall St. Rank held bluebird bio as of Q4 2023.

Based on Caption Management's 13F filing for Q4 2023, filed 14 Feb 2024.